Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target

benzinga.com/25/05/45231488/neurocrine-biosciences-ingrezza-q1-sales-more-resilient-than-investors-feared-analysts-boost-price-target

Neurocrine Biosciences Inc. (NASDAQ:NBIX) stock is trading higher on Tuesday after the company reported better-than-expected first-quarter 2025 earnings.
The company on Monday reported adjusted EPS of 70 cents, lower than the $1.20 reported a year ago, beating the consensus of 54…

This story appeared on benzinga.com, 2025-05-06 17:24:29.
The Entire Business World on a Single Page. Free to Use →